4-{[(3S)-1-azabicyclo[2.2.2]octan-3-yl]amino}-3-(1H-1,3-benzodiazol-2-yl)-6-chloro-1,2-dihydroquinolin-2-one

• ChemBase编号: 73127
• 分子式: C23H22ClN5O
• 平均质量: 419.90668
• 单一同位素质量: 419.15128803
• SMILES: c1(=O)c(c(c2c([nH]1)ccc(c2)Cl)N[C@H]1C2CCN(C1)CC2)c1nc2c([nH]1)cccc2
• Canonical SMILES: Clc1ccc2c(c1)c(N[C@@H]1CN3CCC1CC3)c(c(=O)[nH]2)c1nc2c([nH]1)cccc2
• InChI: InChI=1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)/t19-/m1/s1
• InChIKey: MOVBBVMDHIRCTG-LJQANCHMSA-N

名称和登记号

名称

• IUPAC标准名: 4-{[(3S)-1-azabicyclo[2.2.2]octan-3-yl]amino}-3-(1H-1,3-benzodiazol-2-yl)-6-chloro-1,2-dihydroquinolin-2-one
• IUPAC传统名: 4-[(3S)-1-azabicyclo[2.2.2]octan-3-ylamino]-3-(1H-1,3-benzodiazol-2-yl)-6-chloro-1H-quinolin-2-one
• 别名: CHIR-124

登记号

• CAS号: 405168-58-3
• PubChem SID: 162038047
• PubChem CID: 11502647

理论计算性质

• Acid pKa: 7.951678
• 质子受体: 4
• 质子供体: 3
• LogD (pH = 5.5): 0.59624654
• LogD (pH = 7.4): 2.3285644
• Log P: 2.5454702
• 摩尔折射率: 119.2185 cm^3
• 极化性: 46.08746 Å^3
• 极化表面积: 73.05 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

分子性质

安全信息

• 保存条件: -20°C

药理学性质

• 作用靶点: CDK

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S2683

Biological Activity

• Description: CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM.
• Targets: Chk1
• IC50: 0.3 nM ^[1]
• In Vitro: CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of Chk1. CHIR-124 interacts synergistically with topoisomerase poisons (e.g., Camptothecin or SN-38) in causing growth inhibition in a variety of cancer cell lines, including breast carcinoma (MDA-MB-231 and MDA-MB-435) and colon carcinoma (SW-620 and Colo205), all of which contains the mutant p53 gene. CHIR-124 abrogates the SN-38-induced S and G2-M checkpoints and potentiates apoptosis in MDA-MD-435 breast cancer cells. The abrogation of the G2-Mcheckpoint and induction of apoptosis by CHIR-124 are enhanced by the loss of p53. ^[1] CHIR-124 also potently targets other kinases such as PDGFR and Flt3 with IC50 of 6.6 nM and 5.8 nM, respectively. ^[2]
• In Vivo: CHIR-124 potentiates the growth inhibitory effects of Irinotecan by abrogating the G₂-M checkpoint and increasing tumor apoptosis in an orthotopic breast cancer xenograft model.

Protocol

• Protocol: Kinase Assay ^[1]
• Chk1 Assay: For the Chk1 assay, the kinase domain is expressed in Sf9 insect cells, and a biotinylated cdc25c peptide containing the consensus Chk1/Chk2 phosphorylation site (*)(biotin-[AHX]SGSGS*GLYRSPSMP-ENLNRPR[CONH2]) is used as the substrate. A dilution series of CHIR-124 is mixed with a kinasereaction buffer containing a final concentration of 30 mM Tris-HCl(pH 7.5), 10 mM MgCl₂, 2 mM DTT, 4 mM EDTA, 25 mMβ-glycerophosphate, 5 mM MnCl₂, 0.01% bovine serum albumin, 1.35 nM CHK1 kinase domain, 0.5 μM peptide substrate, and 1 AM unlabeled ATP, plus 5 nM ^33Pγ-labeled ATP (specific activity = 2,000 Ci/mmol). Reactions and detection of the phosphate transfer are carried out by a radioactive method. Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mMHEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled anti-phosphotyrosine antibody PT66. The concentration of CHIR-124 for IC50 is calculated using nonlinear regression with XL-Fit data analysis software.
• Protocol: Cell Assay ^[1]
• Cell Lines: MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells
• Concentrations: 0-2350 nM, dependent on cell types
• Incubation Time: 48 hours
• Methods: MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells in log-phase are plated into 96-well microplates. CHIR-124 is serially diluted in the presence of six different concentrations of Camptothecin or 0 nM camptothecin. Camptothecin is also serially diluted in the absence of CHIR-124. CHIR-124 is added to cells in 96-well dishes and incubated at 37 °C for 48 hours. Each treatment condition is done in triplicate. Cell proliferation was monitored by the 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), inner salt assay. MTS inner salt is added to the microplates, which are incubated for another 3 hours, and absorbance at 490 nm is read on a plate reader. The concentrations of each drug in the combinations required to produce 50% inhibition are plotted to generate the isoboles. Isobologram analysis of drug interaction is based the equation of Loewe additivity (1= D _A /IC50, _A + D_B/IC50, _B), where IC50, _A and IC50, _B are the concentrations of drugs to result in 50% inhibition for each drug alone, and D_A and D_B are concentrations of each drug in the combination that yield 50% overall inhibition. A diagonal line indicating Loewe additivity is included in each graph. Data points that fall below the line indicate synergy, whereas those that fall above the line will indicate antagonism.
• Protocol: Animal Study ^[1]
• Animal Models: MDA-MB-435 cells are implanted in the mammary fat pad of 8- to 10-week-old female immunodeficient mice.
• Formulation: CHIR-124 is dissolved in dimethyl sulfoxide and stored in aliquots at -20 °C.
• Doses: 10 mg/kg or 20 mg/kg
• Administration: CHIR-124 is given orally four times daily × 6 on days 2 to 7 in captisol.

References

• References: [1] Tse AN, et al, Clin Cancer Res, 2007, 13(2 Pt 1), 591-602.
• References: [2] Dai Y, et al, Clin Cancer Res, 2010, 16(2), 376-383

参考文献

• Tse AN, et al, Clin Cancer Res, 2007, 13(2 Pt 1), 591-602.
• Dai Y, et al, Clin Cancer Res, 2010, 16(2), 376-383